ZA201107350B - Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives - Google Patents

Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives

Info

Publication number
ZA201107350B
ZA201107350B ZA2011/07350A ZA201107350A ZA201107350B ZA 201107350 B ZA201107350 B ZA 201107350B ZA 2011/07350 A ZA2011/07350 A ZA 2011/07350A ZA 201107350 A ZA201107350 A ZA 201107350A ZA 201107350 B ZA201107350 B ZA 201107350B
Authority
ZA
South Africa
Prior art keywords
imidazo
thiadiazole derivatives
thiadiazole
derivatives
Prior art date
Application number
ZA2011/07350A
Other languages
English (en)
Inventor
Fernandez Joaquin Pastor
Guido Kurz
Gonzalez Sonia Martinez
Original Assignee
Centro Nac De Investig Oncologicas (Cnio)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Investig Oncologicas (Cnio) filed Critical Centro Nac De Investig Oncologicas (Cnio)
Publication of ZA201107350B publication Critical patent/ZA201107350B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
ZA2011/07350A 2009-04-02 2011-10-07 Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives ZA201107350B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09380069 2009-04-02
PCT/GB2010/000674 WO2010112874A1 (en) 2009-04-02 2010-04-01 Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives

Publications (1)

Publication Number Publication Date
ZA201107350B true ZA201107350B (en) 2015-06-24

Family

ID=40750794

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/07350A ZA201107350B (en) 2009-04-02 2011-10-07 Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives

Country Status (23)

Country Link
US (1) US8815918B2 (enExample)
EP (1) EP2414369B1 (enExample)
JP (1) JP5615902B2 (enExample)
KR (1) KR101727264B1 (enExample)
CN (1) CN102388055B (enExample)
AU (1) AU2010231162B2 (enExample)
BR (1) BRPI1015367B8 (enExample)
CA (1) CA2756873C (enExample)
CY (1) CY1116880T1 (enExample)
DK (1) DK2414369T3 (enExample)
EA (1) EA022753B1 (enExample)
ES (1) ES2548571T3 (enExample)
HR (1) HRP20151126T1 (enExample)
HU (1) HUE027964T2 (enExample)
IL (1) IL215158A (enExample)
MX (1) MX2011010372A (enExample)
NZ (1) NZ595674A (enExample)
PL (1) PL2414369T3 (enExample)
PT (1) PT2414369E (enExample)
SG (1) SG175001A1 (enExample)
SI (1) SI2414369T1 (enExample)
WO (1) WO2010112874A1 (enExample)
ZA (1) ZA201107350B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
GB2480815A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
AU2011260097B2 (en) 2010-06-01 2015-01-22 Summit (Oxford) Limited Compounds for the treatment of clostridium difficile associated disease
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
BR112013008259A2 (pt) 2010-10-06 2017-12-12 Glaxosmithkline Llc composto, composição farmacêutica, e, uso de um composto
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
NZ618157A (en) 2011-05-19 2015-07-31 Fundación Ct Nac De Investigaciones Oncológicas Carlos Iii Macrocyclic compounds as protein kinase inhibitors
KR101399484B1 (ko) 2011-07-14 2014-05-29 한국화학연구원 허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
ES2818107T3 (es) * 2014-08-29 2021-04-09 Chdi Foundation Inc Sondas para obtener imágenes de la proteína huntingtina
PT3186233T (pt) 2014-08-29 2021-12-02 Chdi Foundation Inc Sondas para imagem de proteína de huntingtina
CN112752761B (zh) * 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
CR20210175A (es) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
BR112022007404A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Compostos e composições para o tratamento de doenças parasíticas
EP4210697A1 (en) * 2020-09-14 2023-07-19 The University of Sussex Small molecule inhibitors of lemur tyrosine kinase 3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3208437A1 (de) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
WO1997011075A1 (en) 1995-09-22 1997-03-27 Takeda Chemical Industries, Ltd. Triazole compounds, their production and use
JP2004505983A (ja) * 2000-08-09 2004-02-26 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法
CA2364985A1 (en) 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
KR101075812B1 (ko) 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서의 트리아졸로피리다진
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2527906A1 (en) 2003-06-13 2004-12-23 Aegera Therapeutics, Inc. Acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides and uses thereof
CA2527903A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics, Inc. Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxides and sulfones
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
ES2441178T3 (es) 2005-06-01 2014-02-03 Ucb Pharma, S.A. Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
JP2009533359A (ja) 2006-04-13 2009-09-17 エーゲラ セラピューティクス インク． 神経障害性疼痛を治療するためのイミダゾ［２，１−ｂ］−１，３，４−チアジアゾール−２−スルホンアミド化合物の使用
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
WO2007136736A2 (en) 2006-05-19 2007-11-29 Codon Devices, Inc. Methods for nucleic acid sorting and synthesis
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
MX2009002171A (es) 2006-08-30 2009-05-28 Cellzome Ltd Derivados de triazol como inhibidores de cinasas.
US20110021513A1 (en) 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US7732468B2 (en) * 2006-11-15 2010-06-08 Cytovia, Inc. 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CN101037445A (zh) 2007-04-14 2007-09-19 西北师范大学 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
EA200901488A1 (ru) 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR101156845B1 (ko) 2007-05-21 2012-06-18 에스지엑스 파마슈티컬스, 인코포레이티드 헤테로시클릭 키나제 조절제
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
ES2548768T3 (es) * 2007-09-27 2015-10-20 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Imidazolotiadiazoles para su uso como inhibidores de proteína quinasa
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
EP2307425B1 (en) 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives

Also Published As

Publication number Publication date
ES2548571T3 (es) 2015-10-19
PT2414369E (pt) 2015-10-22
CA2756873A1 (en) 2010-10-07
SG175001A1 (en) 2011-11-28
BRPI1015367A2 (pt) 2018-02-20
PL2414369T3 (pl) 2016-04-29
SI2414369T1 (sl) 2015-12-31
JP2012522759A (ja) 2012-09-27
US20120094996A1 (en) 2012-04-19
EP2414369B1 (en) 2015-08-12
AU2010231162A1 (en) 2011-11-03
CY1116880T1 (el) 2017-04-05
HRP20151126T1 (hr) 2015-11-20
DK2414369T3 (en) 2015-09-21
US8815918B2 (en) 2014-08-26
HUE027964T2 (en) 2016-11-28
CN102388055B (zh) 2015-07-29
MX2011010372A (es) 2012-01-12
EA022753B1 (ru) 2016-02-29
CA2756873C (en) 2018-01-09
IL215158A0 (en) 2011-12-29
NZ595674A (en) 2012-12-21
AU2010231162B2 (en) 2014-12-11
BRPI1015367B1 (pt) 2021-05-11
EP2414369A1 (en) 2012-02-08
CN102388055A (zh) 2012-03-21
HK1166979A1 (zh) 2012-11-16
JP5615902B2 (ja) 2014-10-29
EA201101435A1 (ru) 2012-04-30
IL215158A (en) 2015-07-30
KR20120034607A (ko) 2012-04-12
WO2010112874A1 (en) 2010-10-07
BRPI1015367B8 (pt) 2021-05-25
KR101727264B1 (ko) 2017-04-14

Similar Documents

Publication Publication Date Title
ZA201107350B (en) Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives
DK3178819T3 (en) 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-carboxamider som jak-inhibitorer
AP2011005807A0 (en) 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-inflammatory agents.
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
IL213920A0 (en) 3,3'-spiroindolinone derivatives as anticancer agents
IL216007A0 (en) Isoxazole-pyridine derivatives
GB0702259D0 (en) 7-azaindole derivatives
IL211241A0 (en) 7-azaindole derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
EP2500345A4 (en) 8-azabicyclo [3.2.1-] octan-8-carboxamide
SI2513119T1 (sl) 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
EP2448934A4 (en) DERIVATIVES OF 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN
IL221479A0 (en) Triazolo [4,5-b] pyridin derivatives
IL216761A0 (en) Pyrazinooxazepine derivatives
IL212942A0 (en) Rifamycin derivatives
IL219603A0 (en) Imidazopyridine derivatives
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
GB0702265D0 (en) 7-Azaindole derivatives